ProCE Banner Activity

Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Slideset Download
Download these expert-selected slides on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings.

Released: October 05, 2022

Expiration: October 04, 2023

No longer available for credit.

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.
ProCE Banner

Supporters

This CE activity is supported through an educational grant from

AstraZeneca

BeiGene

Lilly

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

consultant/advisor: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Dava Oncology, Epizyme, Genentech, Gilead Sciences, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, MEI Pharma, Merck, Pharmacyclics, Verastem.

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Pharmacyclics.